Australia's most trusted
source of pharma news
Posted 10 December 2025 AM
A JAK inhibitor without a dose-limiting side effect is on the cards thanks to powerful quantum chemistry simulations developed by Australian researchers that identified a highly specific target site.
The drug is so promising that its developer, Prelude, signed an option agreement with Incyte for the latter to acquire the program in November, receiving US$35 million up front and a US$25 million strategic equity investment. A further US$100 million is payable if Incyte exercises its option, and up to US$775 million in additional potential milestones plus royalties on net sales.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.